U.S. Markets closed
  • S&P 500

    4,166.45
    -55.41 (-1.31%)
     
  • Dow 30

    33,290.08
    -533.37 (-1.58%)
     
  • Nasdaq

    14,030.38
    -130.97 (-0.92%)
     
  • Russell 2000

    2,237.75
    -49.71 (-2.17%)
     
  • Crude Oil

    71.50
    +0.46 (+0.65%)
     
  • Gold

    1,763.90
    -10.90 (-0.61%)
     
  • Silver

    25.84
    -0.01 (-0.04%)
     
  • EUR/USD

    1.1865
    -0.0045 (-0.3797%)
     
  • 10-Yr Bond

    1.4500
    -0.0610 (-4.04%)
     
  • Vix

    20.70
    +2.95 (+16.62%)
     
  • GBP/USD

    1.3809
    -0.0115 (-0.8272%)
     
  • USD/JPY

    110.1500
    -0.0810 (-0.0735%)
     
  • BTC-USD

    35,540.70
    -614.48 (-1.70%)
     
  • CMC Crypto 200

    888.52
    -51.42 (-5.47%)
     
  • FTSE 100

    7,017.47
    -135.96 (-1.90%)
     
  • Nikkei 225

    28,964.08
    -54.25 (-0.19%)
     

Today’s Research Reports on Stocks to Watch: Oragenics and Pfizer

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / September 24, 2018 / It was a good day for biotech stocks Pfizer and Oragenics this past Friday. While Oragenics did not have any news, the company is expected to present data today. Shares of Pfizer hit a brand new high after the company announced it had received Breakthrough Therapy designation for PF-06482077.

RDI Initiates Coverage on:

Pfizer Inc.
https://www.rdinvesting.com/report/?ticker=PFE

Oragenics, Inc.
https://www.rdinvesting.com/report/?ticker=OGEN

Pfizer Inc. shares hit a brand new high of $44.19 on Friday on roughly 35 million shares traded. Average trading volume for the pharmaceutical giant is just under 19.6 million shares. The company recently announced that it has received Breakthrough Therapy designation for its 20-valent pneumococcal conjugate vaccine (20vPnC) candidate, PF-06482077, from the Food and Drug Administration. PF-06482077 is being developed as a preventive treatment for invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes in adult patients. "We look forward to continuing our dialogue with the FDA so that we can accelerate the development program of the adult indication of Pfizer’s 20-valent next-generation pneumococcal vaccine candidate," said Kathrin U. Jansen, Ph.D., Senior Vice President and Head of Vaccine Research & Development, Pfizer. "There continues to be a global health need to protect against the potentially devastating effects of invasive pneumococcal disease and pneumonia caused by additional serotypes, and we are dedicated to continue to build on our expertise in pneumococcal conjugate vaccines with this vaccine candidate."

Access RDI’s Pfizer Inc. Research Report at:
https://www.rdinvesting.com/report/?ticker=PFE

Oragenics, Inc. closed up nearly 46% on about 15 million shares traded this past Friday. The big gains may have been the result of traders being eager for the company to present data today. Dr. Martin Handfield, the company’s senior vice president of discovery research has been expected to present data on the company's lantibiotics program for the treatment of serious and prevalent infectious diseases at the Boulder Peptide Symposium on Monday, September 24, 2018 at 12:55 PM MT at the St. Julien Hotel and Spa in Boulder, CO. “We look forward to sharing data we have collected regarding OG716 and our lantibiotics program at such a prestigious event as the Boulder Peptide Showcase,” stated Dr. Alan Joslyn, president and CEO of Oragenics, Inc. The company has identified OG716 as the lead compound against Clostridium difficile associated disease. In pre-clinical studies, OG716 showed an in vitro potency equal or superior to "standard of care" drugs against drug-resistant bacteria, in addition to better safety, toxicity, stability profiles and adequate manufacturability.

Access RDI’s Oragenics, Inc. Research Report at:
https://www.rdinvesting.com/report/?ticker=OGEN

Our Actionable Research on Oragenics, Inc. (NYSE: OGEN) and Pfizer Inc. (NYSE: PFE) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com